---
document_datetime: 2024-08-01 16:58:25
document_pages: 34
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neupro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: neupro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 20.2148706
conversion_datetime: 2025-12-24 23:08:19.270103
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Neupro

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|--------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IB/0098              | B.II.z - Quality change - Finished product - Other variation | 31/07/2024                          |                                             | SmPC, Labelling and PL           |                                                                                                                        |
| PSUSA/2667/ 202302   | Periodic Safety Update EU Single assessment - rotigotine     | 12/10/2023                          | 07/12/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     | PSUSA/2667/202302.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IA/0096/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                   | 19/04/2023 | n/a |                      |
| IA/0095   | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                   | 01/02/2023 | n/a |                      |
| WS/2350/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.z - Change in the specification parameters | 13/10/2022 | n/a |                      |
| IA/0093   | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/02/2022 | n/a |                      |
| IB/0091   | A.z - Administrative change - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/02/2022 | n/a |                      |

<div style=\"page-break-after: always\"></div>

| IA/0092   | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                | 10/12/2021   | n/a        |             |                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------|
| N/0090    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                           | 08/11/2021   | 04/02/2022 | PL          |                   |
| WS/2000   | application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH significant assessment is required | 11/02/2021   | n/a        |             | This was an where |
| WS/1963   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                            | 14/01/2021   | 04/02/2022 | SmPC and PL |                   |
| IA/0088   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                               | 09/12/2020   | n/a        |             |                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/2667/ 202002   | Periodic Safety Update EU Single assessment - rotigotine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/10/2020   | n/a        |             | PRAC Recommendation - maintenance   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| WS/1689              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                   | 16/01/2020   | 11/01/2021 | SmPC and PL |                                     |
| WS/1602/G            | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS | 04/07/2019   | n/a        |             |                                     |
| IG/1072              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/02/2019   | n/a        |             |                                     |

<div style=\"page-break-after: always\"></div>

| WS/1381            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to add an adverse drug reaction: Dropped Head Syndrome based on new pharmacovigilance data; The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to correct some discrepancies found within the PIL of Greece, Cyrus and Romania and to update the Neupro Annex A in alignment with Leganto Annex A for the description of the multipack size. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 07/06/2018   | 08/11/2018   | SmPC and PL            |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2667/ 201702 | Periodic Safety Update EU Single assessment - rotigotine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/10/2017   | 11/12/2017   |                        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2667/201702. |
| WS/1238/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.z - Change in container closure system of the Finished Product - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 09/11/2017   | 08/11/2018   | SmPC, Labelling and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IAIN/0081   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 20/10/2017   | 08/11/2018   | Annex II and PL        |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| T/0080      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/08/2017   | 28/09/2017   | SmPC, Labelling and PL |
| N/0074      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/06/2017   | 28/09/2017   | PL                     |
| IAIN/0078/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within | 01/06/2017   | 28/09/2017   | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|           | - Change in pack size of the finished - Change in the number of units (e.g. ampoules, etc.) in a pack - Change within range of the currently approved pack sizes                                                                                                                                                                                           |            |            |                        | B.II.e.5.a.1 product tablets, the   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------|
| IAIN/0076 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                         | 01/06/2017 | 28/09/2017 | SmPC, Labelling and PL |                                     |
| WS/0950   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions | 10/11/2016 | n/a        |                        |                                     |
| N/0073    | Update of the package leaflet with revised contact details of the local representatives for Lithuania, Estonia, Latvia, Portugal and Finland. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 08/11/2016 | 16/02/2017 | PL                     |                                     |
| IG/0710   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                               | 26/07/2016 | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/0886/G   | This was an application for a group of variations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/02/2016   | 16/02/2017   | SmPC, Labelling and PL   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
|             | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.a.3.b.5 - Changes in the composition (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished |              |              |                          |

<div style=\"page-break-after: always\"></div>

| B.II.b.5.z - Change to applied during the manufacture product - Other variation B.II.c.1.a - Change in and/or limits of an excipient specification limits B.II.c.2.a - Change in - Minor changes to an B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.II.d.1.z - Change in and/or limits of the finished B.II.d.1.z - Change in and/or limits of the finished B.II.d.1.z - Change in and/or limits of the finished B.II.d.1.z - Change in and/or limits of the finished B.II.d.1.z - Change in and/or limits of the finished B.II.d.2.a - Change in   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0069    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/11/2015 | 22/01/2016 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Neupro continues to be favourable. The CHMP is of the opinion that the renewal can be granted with unlimited validity. |
| WS/0751/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of two final reports of studies which investigated the potential risk of cardiovalvular fibrosis in Parkinson's disease patients treated with rotigotine. The RMP version 4 is updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 25/06/2015 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                              |
| WS/0684   | This was an application for a variation following a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/02/2015 | 22/01/2016 | SmPC and PL                      | A safety signal assessment to evaluate the association of                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC to include the adverse event 'dopamine dysregulation syndrome'. The package leaflet is amended accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                     |            |            |             | dopamine dysregulation syndrome (DDS) with rotigotine was recently conducted and this safety signal was confirmed. As a result, the rotigotine company core data sheet (CCDS) was updated to include DDS as an additional AE term under undesirable effects. Consequently, the product information has been updated in this type II variation to include DDS.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0674   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2 and 5.2 of the SmPC to amend information about the paediatric population following the conduct of a dose-escalation Study SP1004 in paediatric patients with Idiopathic Restless Legs Syndrome. Section 4.2 is updated in line with the current QRD template for paediatric information. The MAH also took the opportunity to make minor editorial corrections in the package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/02/2015 | 22/01/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0520/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/01/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |             |                                                                                                                                                                                                                                                                                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0659   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To include an alternative manufacturer of the starting material for the active substance. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                          | 18/12/2014 | n/a        |             | To include an alternative manufacturer of the starting material for the active substance.                                                                                                                                                                                                                                                           |
| PSUV/0063 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                | 25/09/2014 | 19/11/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0063.                                                                                                                                                                                                                   |
| WS/0450   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                            | 23/01/2014 | 19/11/2014 | SmPC and PL | The present Type II variation application was meant to update the rotigotine EU Product Information (Summary of Product Characteristics [SmPC] and Patient Information Leaflet [PIL]) to include the changes made to the CCDS as a result of review of clinical and post-marketing data. CHMP requested that the terms 'delusion' and 'delirium' be |

<div style=\"page-break-after: always\"></div>

|         | data                                                                                                                                                                                                                                                                                                                                     |            |            |                                  | kept in the warning on abnormal thinking and behaviour, and agreed on the changes proposed regarding peripheral oedema, agitation, impulse control disorders and hypersensitivity reactions. Additionally, editorial and orthographical changes have been made in SmPC sections 4.2, 4.4, 4.8 and 5.1 to facilitate reading. The patient leaflet was amended to align with the SmPC changes outlined above.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0385 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the PI in line with QRD template 9.0. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                             | 27/06/2013 | 31/07/2013 | SmPC, Annex II, Labelling and PL | All parts of the product information were brought in line with QRD template 9.0 including standard text to encourage reporting of adverse reactions by healthcare professionals and patients as well as the update of Annex II to reflect the requirement of PSUR submissions in line with the EURD list and of RMP updates.                                                                                  |
| WS/0394 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the specification limits of the finished product. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 27/06/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                               |
| IG/0222 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                           | 16/11/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| WS/0293   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC in order to include summary descriptions of two clinical studies in relation to the use of equipotent doses for rotigotine as compared to ropinirole and other dopamine agonists as well as to amend the wording on the comparability of efficacy of rotigotine versus ropinirole, as observed in one of the pivotal trials. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 15/11/2012   | 14/01/2013   | SmPC        | The update is based on data from two clinical trials, supported by three additional studies, investigating the efficacy and safety of rotigotine patches in equipotent doses to the oral dopamine agonists ropinirole, pramipexole and cabergoline. One of the studies indicated that effective control of Parkinson's disease symptoms can be achieved when switching from an oral dopamine agonists to rotigotine patch. Section 5.1 of the SmPC was updated to reflect relevant information on these two studies and to correct a statement on the comparability of efficacy of rotigotine and ropinirole observed in a previous pivotal trial.                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0286/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information in relation to binge eating and aggression and to implement a class labelling for impulse control disorders. The Package Leaflet was updated in accordance. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with                                                   | 15/11/2012   | 14/01/2013   | SmPC and PL | Following a request from the CHMP based on the review of PSUR data, aggression/aggressive behaviour as well as binge eating and compulsive eating were included as rare adverse reactions in the product information. Furthermore, based on a recent review of the available post-marketing data in relation to the risk of development of impulse control disorders when using medicinal products containing levodopa, dopamine agonists and/or Catechol-O- methyltransferase (COMT) inhibitors, the CHMP/PhVWP recommended a class labelling to update and harmonise the product information of all products concerned. To this end, the product information was updated to reflect related behavioural symptoms including compulsive spending or buying, binge eating and compulsive eating and that the adverse reaction can occur irrespective of the indication |

<div style=\"page-break-after: always\"></div>

|           | NO new additional data are submitted by the MAH C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  | and at normal doses. Regular monitoring of patients and a careful review of treatment, if symptoms occur, is recommended. The Package Leaflet was updated in accordance and advice for the patient's family and carers was provided.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0226/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - to change the quantitative composition of the rotigotine transdermal patches for some excipients included in the drug containing self adhesive mass of the reformulated product. - to update the manufacturing process for the reformulated product. - to replace the details of the current approved batch sizes. - to add an editorial update to replace details formerly approved for a theoretical batch size. - to remove some of the current approved details to align with current manufacturing practice. - to tighten some specification limits. - to update the specification for compendial excipients to include USP and/or USP-NF testing in addition to current approved Ph.Eur. - to update some of non-compendial excipients. - to update some of the release and shelf-life | 19/07/2012 | 23/08/2012 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| - to tighten some of the - to tighten some of the specification limits. - to delete some of testing shelf-life specifications. - to update the release drug release. - to change the some test - to change some the analytical - to change the storage reformulated, room temperature 'store in a refrigerator above 25C'. - to extend the shelf life 18 months to 24 months. B.II.a.3.b.5 - Changes (excipients) of the finished - Change that is supported B.II.b.3.b - Change in the the finished product - Substantial manufacturing process impact on the quality, safety medicinal product B.II.b.4.z - Change in the size ranges) of the finished B.II.b.5.a - Change to applied during the manufacture product - Tightening of B.II.b.5.a - Change to applied during the manufacture   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

B.II.b.5.a  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Tightening of in-process  limits B.II.b.5.b  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Addition  of a new tests and limits B.II.b.5.b  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Addition  of a new tests and limits B.II.b.5.c  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Deletion  of a non-significant  in-process  test B.II.b.5.c  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Deletion  of a non-significant  in-process  test B.II.b.5.c  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Deletion  of a non-significant  in-process  test B.II.b.5.c  - Change  to in-process  tests or limits applied  during the manufacture  of the finished product - Deletion  of a non-significant  in-process  test B.II.b.5.z  - Change to in-process  tests or limits applied  during the manufacture  of the finished product - Other variation B.II.b.5.z  - Change to in-process  tests or limits applied  during the manufacture  of the finished product - Other variation B.II.c.1.a  - Change  in the specification  parameters and/or  limits of  an excipient  - Tightening of specification  limits B.II.c.1.a  - Change  in the specification  parameters and/or  limits of  an excipient  - Tightening of

<div style=\"page-break-after: always\"></div>

| specification limits B.II.c.1.c - Change in and/or limits of an excipient significant specification an obsolete parameter) B.II.c.1.c - Change in and/or limits of an excipient significant specification an obsolete parameter) B.II.c.1.z - Change in and/or limits of an excipient B.II.c.1.z - Change in and/or limits of an excipient B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.d - Change in and/or limits of the finished non-significant specification of an obsolete parameter B.II.d.1.e - Change in and/or limits of the finished   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method   |            |            |                  |                                                                                                                                                                                                                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0054  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/12/2011 | 26/03/2012 | Labelling and PL |                                                                                                                                                                                                                                  |
| IG/0129 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/12/2011 | n/a        |                  |                                                                                                                                                                                                                                  |
| II/0052 | Section 5.1 of the SPC is proposed to be updated to include new clinical data from a phase 3 study to evaluate the effect of rotigotine on early morning motor function, sleep quality, nocturnal symptoms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/07/2011 | 24/08/2011 | SmPC             | The MAH conducted a Phase 3, double-blind, placebo- controlled, 2-arm trial of rotigotine in 287 subjects with early-stage or advanced-stage idiopathic Parkinson's disease. The purpose of the trial was to evaluate the effect |

<div style=\"page-break-after: always\"></div>

|         | and non-motor symptoms in subjects with idiopathic Parkinson's disease. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                    |            |            |                                  | of transdermal delivery of rotigotine on the control of early morning motor function, sleep quality, nocturnal symptoms, and non-motor symptoms in subjects with idiopathic Parkinson's disease. Subjects were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2mg/24h, starting at 2mg/24h, to a maximum dose of 16mg/24h over 8 weeks, followed by a maintenance period of 4 weeks. A statistically significant improvement was seen in the co-primary outcome measures early morning motor function, assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, and nocturnal sleep disturbances, measured by the modified Parkinson's Disease Sleep Scale (PDSS-2).   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0051 | Section 5.1 of the SmPC is proposed to be updated to provide a more precise description of rotigotine activity at dopamine and 5-HT1A receptors, and to provide more information regarding the mode of action for the treatment of Restless Legs Syndrome. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/07/2011 | 24/08/2011 | SmPC                             | Section 5.1 of the SmPC has been amended to provide a more precise description of the rotigotine activity and mechanism of action for rotigotine in regards to dopamine and 5HTA1 receptors. This change is editorial and not based on new data presented. Based on Cerep study 817014 submitted in support of this application, a statement has been added regarding 5HT2B receptor activity of rotigotine. Finally, more information with regard to the mode of action of rotigotine as a treatment of Restless Legs Syndrome (RLS) has been added to section 5.1.                                                                                                                                                      |
| II/0050 | The SmPC is proposed to be updated in section 4.9 to provide more information regarding handling of suspected overdose, and in section 5.2 to provide information about the biphasic elimination of rotigotine. In addition, section 4.8 has been updated to precise the study data base used for the ADR table, and a statement on the post-marketing                                                            | 21/07/2011 | 24/08/2011 | SmPC, Annex II, Labelling and PL | The SmPC has been updated in section 5.2 to provide information about the biphasic elimination of rotigotine. In support of this change, the MAH conducted two studies to verify that a two compartment model would fit the concentrations obtained after patch removal. Section 4.9 has been amended to provide more information regarding handling of suspected overdose, and the PL has been                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | experience has been added. The patient leaflet has been amended for overdose handling in section 3 and 'involuntary movements' and 'convulsions' have been added as likely side effects caused by overdosing in this section. Annex II has been amended to be in line with the current QRD template, and the version number of the RMP has been updated. In addition, a few typographical errors have been corrected in the annexes. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |                                  | aligned with the SmPC with regards to overdose symptoms. Section 4.8 has been updated to precise the study data base used for the ADR table. In addition, a statement on the post-marketing experience has been added to section 4.8.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0053/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                         | 24/08/2011 | n/a        | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                         |
| II/0046/G | This was an application for a group of variations. Change to the specifications of the finished product and deletion and update to test methods. B.II.d.1.f - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                          | 19/05/2011 | 19/05/2011 |                                  |                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised                                              |            |     |                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IA/0049/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 04/05/2011 | n/a | the pharmacovigilance system |
| IA/0047/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished control sites (excluding                                                                                                 | 06/04/2011 | n/a | product, including quality   |

<div style=\"page-break-after: always\"></div>

|           | manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044   | Section 4.4 of the SPC has been amended to reflect long term study data on augmentation generated in patients with restless legs syndrome (RLS). This amendment was requested by the CHMP following submission of study SP710 data to address augmentation (FUM020). In addition, the version number of the RMP has been updated, and the version number of the DDPS has been deleted from Annex IIB of the Product Information as recommended by the EMA. The list of contact details for the local representatives in the PL has also been updated. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the | 20/01/2011 | 21/02/2011 | SmPC, Annex II and PL | With this variation application, section 4.4 of the Neupro SPC has been amended to reflect long term study data on augmentation generated in patients with restless legs syndrome (RLS). This amendment was requested by the CHMP following submission of a case-by-case analysis of study SP710 data to address augmentation (FUM020). Analysis of a 5-year open-label treatment study showed that augmentation occurred in 11.9% of patients treated with the approved dosages for RLS (1-3 mg/24 h), and that 5.1% were considered clinically significant. The majority of augmentation episodes occurred in the first and second years of treatment. This study also allowed 4 mg/24 h dosing, which showed higher rates of augmentation. The 4 mg/24 h dosage is, however, not approved for the treatment of RLS. |
| IB/0045/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall                                                                                                                                                                                                                                                                                                                                                                                               | 14/12/2010 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | of the AS - Change to in-process tests or limits during the manufacture of the AS - Deletion a non-significant in-process test                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  | quality B.I.a.4.c applied of   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------|
| R/0040    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/09/2010 | 29/11/2010 | SmPC, Annex II, Labelling and PL |                                |
| IB/0039   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                        | 03/06/2010 | n/a        |                                  |                                |
| IB/0042   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26/05/2010 | n/a        | SmPC                             |                                |
| IA/0041/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities | 21/05/2010 | n/a        | Annex II                         |                                |

<div style=\"page-break-after: always\"></div>

|         | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0038 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/05/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0037 | Update of section 4.8 of the Summary of Product Characteristics (SPC) to bring the section in line with MedDRA version 9.1. Section 4.4 was amended to include a warning on allergic type reactions associated with sodium metabisulphite (E223) and to update the information on neuroleptic malignant syndrome. Additions are proposed to Restless Legs Syndrome (RLS) specific paragraphs in section 4.4 and 5.1 of the SPC for the 2 mg/24 h patch to distinguish the information presented for RLS from that for Parkinson's disease. Relevant sections of the Labelling and Package Leaflet (PL) have been amended accordingly. In addition, minor typographical errors have been corrected in the PL. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 21/01/2010 | 15/03/2010 | SmPC, Labelling and PL | Following the assessment of PSUR 5, the CHMP requested the MAH to revise section 4.8. Specifically, ADRs terms have been removed or newly included and frequencies have been updated. For some terms the assignment to a system organ class (SOC) has been changed as defined in the updated MedDRA version 9.1. Safety data have been presented for each indication, in order to avoid presenting both Restless Legs Syndrome (RLS) and Parkinson's disease (PD) data in formulations that have only one of these two indications (1 and 3 mg for RLS and 4, 6 and 8 mg for PD). Section 4.4 was also amended to include a warning on allergic type reactions associated with sodium metabisulphite (E223) and to update the information on neuroleptic malignant syndrome. Relevant sections of the Labelling and Package Leaflet have been amended accordingly. |
| N/0036  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/10/2009 | n/a        | Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0035   | Update of section 4.8 of Summary of Product Characteristics (SPC) to include information on                                                                                                                                                        | 23/07/2009   | 31/08/2009   | SmPC   | Following the assessment of the results from a case-by- case analysis on SP791 and SP793 ( open label extension                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034   | Update of section 4.8 of Summary of Product Characteristics (SPC) to include information on discontinuation rates at the CHMP request. This update is based on results of clinical studies SP791, SP793 and additional 3-year data from an ongoing | 23/07/2009   | 31/08/2009   | SmPC   | Following the assessment of the results from open label extension studies SP790 and SP793, the CHMP concluded that long term data on rotigotine to treat Restless Legs Syndrome (RLS) supported previous evidence on efficacy, safety and tolerability. Moreover, results were not |

<div style=\"page-break-after: always\"></div>

|         | study (SP710) conducted in Restless Legs Syndrome (RLS) patients. Update of Summary of Product Characteristics                                                                                                                                                                                |            |            |          | significantly different between studies. However discontinuation rates were kept high (up to 38%) and the CHMP requested an update of section 4.8 of the SPC to reflect this information. Subsequently the MAH provided additional 3-year data from an ongoing study (SP710) also conducted in RLS patients. At 1 year in SP791, SP793, and SP710, 27%, 38%, and 25% of subjects discontinued from the respective study. At 2 years in SP710, an additional 10% of subjects discontinued, with 65% of subjects remaining in the trial. At 3 years in SP710, an additional 11% of subjects discontinued, with 54% of subjects remaining in the trial. The CHMP therefore recommended the following information to be included in section 4.8 of the SPC: - The discontinuation rate was studied in 3 clinical trials ranging up to 3 years in duration. The percentage of subjects discontinuing was 25-38% over the first year, 10% in the second year, and 11% in the third year. Periodic assessment of efficacy should be performed, along   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) in Module 1.8.1 of the Neupro Marketing Authorisation to version 7.0 dated 5 June 2009. Annex II has been updated to reflect the new version number of the DDPS. Changes to QPPV Update of DDPS (Pharmacovigilance) | 25/06/2009 | 16/07/2009 | Annex II | With this variation the MAH submitted an updated DDPS (version 5.0). After assessing the documentation the CHMP concluded that the submitted DDPS contains all required elements. The Annex II was therefore updated to include the version number of the new DDPS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0030 | This variation refers to the submission of a                                                                                                                                                                                                                                                  | 29/05/2009 | 24/06/2009 | Annex II | As part of a commitment to address the quality defect in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | bioequivalence study (SP951) comparing patches from the originally approved manufacturing process using rotigotine Form 1, with patches manufactured using rotigotine Form 2, according to the new manufacturing process in place and to the lifting of the following restrictions: - pack size limitation : pack size will be limited to no more than 1 month supply; - not to expand/promote the current Parkinson's disease treatment population; - not to pursue the planned launches of Neupro for Parkinson's disease indication in those European (EU) countries where the product is not yet available; - not to launch the product for the indication Restless Legs Syndrome within the EU. Consequently, Annex II is updated to reflect that the related commitments to address the quality defect in relation to the crystal formation in the patches are considered fulfilled.   |            |            |      | relation to crystal formation in the patches, the MAH submitted the results of a bioequivalence study (SP951) and subsequently requested the lifting of the restrictions laid out in the commitments made at the time of Urgent Safety Restriction and article 20 procedure in relation to pack size limitation and initiation of new patient treatment. Based on the review of these data, the CHMP concluded that bioequivalence of rotigotine transdermal patch (4.5mg/10cm2) from the modified manufacturing process using polymorphic form 2 as drug substance for patch production and from the originally approved manufacturing process using polymorphic form 1 as drug substance for patch production was established. Furthermore, taking into account that all the related commitments undertaken by the MAH have been fulfilled to address the quality defect in relation to the crystal formation in the patches, the CHMP recommended the lifting of the restrictions, as requested by the MAH.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/05/2009 | n/a        | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0032 | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/05/2009 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0028 | Change to shelf-life and update to the pharmaceutical documentation. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 19/02/2009 | 02/04/2009 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0029   | The Marketing Authorisation Holder applied to change the drug substance specification to be specific for rotigotine form 2 according to a previous commitment.                       | 19/02/2009   | 06/03/2009   |                        | Quality changes    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------|
| II/0024   | The MAH has applied for changes of the product regarding the storage condition, the shelf life and the release and shelf life specifications following an Urgent Safety Restriction. | 25/09/2008   | 06/11/2008   | SmPC                   | New safety warning |
| IA/0027   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                     | 13/10/2008   | n/a          |                        |                    |
| II/0025   | The MAH has applied for an update of the Drug Substance Part following an Urgent Safety Restriction. Change(s) to the manufacturing process for the active substance                 | 25/09/2008   | 01/10/2008   |                        |                    |
| IB/0026   | IB_10_Minor change in the manufacturing process of the active substance                                                                                                              | 18/09/2008   | n/a          |                        |                    |
| X/0020    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                           | 24/04/2008   | 29/08/2008   | SmPC, Labelling and PL |                    |

<div style=\"page-break-after: always\"></div>

| II/0019   | Extension of indication for Neupro 1mg/24h, 2mg/24h and 3mg/24h transdermal patches to include symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults. Consequential changes are made to all Neupro presentations. Extension of Indication                                                                                                                                                                     | 24/04/2008   | 29/08/2008   | SmPC, Annex II, Labelling and PL   | The CHMP variation assessment report will be published as part of the EPAR, following review/deletion of confidential information.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| A20/0023  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 29 May 2008, the opinion of Committee for Medicinal Products for Human Use (CHMP) on measures necessary to ensure the quality and the effective use of Neupro further to the CHMP review on the reoccurrence of a quality defect (crystal formation up to 40% of the visible surface area of the patch) and its impact on the risk benefit balance. | 03/06/2008   | 04/08/2008   | SmPC, Annex II, Labelling and PL   |                                                                                                                                      |
| N/0022    | Update of the list of local representatives in section 6 of the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                               | 28/01/2008   | n/a          | PL                                 |                                                                                                                                      |
| IB/0021   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                                                                                   | 18/12/2007   | n/a          |                                    |                                                                                                                                      |
| IB/0018   | IB_37_b_Change in the specification of the finished product - add. of new test parameter                                                                                                                                                                                                                                                                                                                                                        | 03/08/2007   | n/a          |                                    |                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IA/0017   | IA_13_a_Change in test proc. for active substance - minor change                                     | 04/06/2007   | n/a   |
|-----------|------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0016   | IA_13_a_Change in test proc. for active substance - minor change                                     | 04/06/2007   | n/a   |
| IA/0015   | IA_13_a_Change in test proc. for active substance - minor change                                     | 04/06/2007   | n/a   |
| IA/0014   | IA_13_a_Change in test proc. for active substance - minor change                                     | 04/06/2007   | n/a   |
| IA/0013   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure       | 04/06/2007   | n/a   |
| IA/0012   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure       | 04/06/2007   | n/a   |
| IA/0011   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure       | 04/06/2007   | n/a   |
| IA/0010   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure       | 04/06/2007   | n/a   |
| IA/0009   | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. | 04/06/2007   | n/a   |
| IB/0008   | IB_12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter        | 16/04/2007   | n/a   |

<div style=\"page-break-after: always\"></div>

| IA/0007   | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/03/2007   | n/a        |                  |                                                                                                                                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|------------------------------------------------------------------------------------------------------------------------------------|
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/02/2007   | n/a        | Labelling and PL |                                                                                                                                    |
| II/0003   | The variation refers to an extension of the therapeutic indication to include 'the treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).' Consequential changes were made to relevant sections of the Summary Product Characteristics (SPC). The Package Leaflet (PL) was updated accordingly. In addition, contact details of Bulgaria and Romania local representatives were also included. Extension of Indication | 16/11/2006   | 09/01/2007 | SmPC and PL      | The CHMP variation assessment report will be published as part of the EPAR, following review/deletion of confidential information. |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/11/2006   | n/a        | PL               |                                                                                                                                    |
| N/0002    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/08/2006   | n/a        | PL               |                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IA/0004   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size   | 02/08/2006   | 02/08/2006   | SmPC, Labelling and PL   |
|-----------|-------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| IA/0001   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                  | 17/05/2006   | n/a          |                          |